Market cap
$25 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.4
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-38 Mln
-
ROE
-0.9 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0.7
-
Debt to Equity
0.3
-
Book Value
$--
-
EPS
$-1.1
-
Face value
--
-
Shares outstanding
43,832,800
6 Years Aggregate
CFO
$-156.23 Mln
EBITDA
$-149.22 Mln
Net Profit
$-150.82 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Metacrine Inc (MTCR)
| 29.8 | 2.4 | 2.0 | 23.7 | -- | -- | -- |
|
BSE Sensex*
| -10.9 | -4.9 | -8.9 | -7.6 | 6.9 | 8.3 | 11.5 |
|
Company
|
2022
|
2021
|
|---|---|---|
|
Metacrine Inc (MTCR)
| -33.5 | -91.4 |
|
BSE Sensex
| 4.4 | 22.0 |
|
BSE Sensex
| 4.4 | 22.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Metacrine Inc (MTCR)
|
0.6 | 25.5 | 0.0 | -39.3 | -- | -94.2 | -- | 0.4 |
| 75.0 | 10,307.9 | 622.0 | -300.9 | -30.1 | -62 | -- | 17.6 | |
| 76.9 | 10,379.7 | 105.8 | -829.6 | -715.0 | -- | -- | 60.5 | |
| 50.2 | 12,233.5 | 2,375.5 | 833.4 | 40.8 | 40.7 | 16.1 | 6.5 | |
| 119.0 | 13,020.0 | 1,080.2 | -433.2 | -39.8 | -- | -- | 60.9 | |
| 68.3 | 8,152.3 | 1,508.5 | 348.8 | 57.0 | 96.4 | 24.1 | 36.2 | |
| 299.5 | 8,785.0 | 417.3 | 225.0 | 42.8 | 18.6 | 39.9 | 6.8 | |
| 517.3 | 11,800.4 | 1,132.5 | -309.4 | -25.5 | -52.9 | -- | 21.7 | |
| 432.8 | 11,992.5 | 2,678.3 | 460.4 | 21.1 | 103.2 | 26.4 | 20.0 | |
| 343.6 | 8,938.2 | 0.0 | -326.5 | -- | -37.2 | -- | 6.3 |
Shareholding Pattern
View DetailsAbout Metacrine Inc (MTCR)
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of... ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California. Read more
-
Pres, CEO & Director
Dr. Preston S. Klassen M.D., M.H.S.
-
Pres, CEO & Director
Dr. Preston S. Klassen M.D., M.H.S.
-
Headquarters
San Diego, CA
-
Website
FAQs for Metacrine Inc (MTCR)
What is the current share price of Metacrine Inc (MTCR) Today?
The share price of Metacrine Inc (MTCR) is $0.58 (NASDAQ) as of 20-Jun-2023 15:11 EDT. Metacrine Inc (MTCR) has given a return of 23.7% in the last 1 years.
What is the current PB & PE ratio of Metacrine Inc (MTCR)?
Since, TTM earnings of Metacrine Inc (MTCR) is negative, P/E ratio is not available.
The P/B ratio of Metacrine Inc (MTCR) is 0.40 times as on 20-Jun-2023, a 90 discount to its peers’ median range of 4.08 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2021
|
-0.30
|
0.32
|
|
2020
|
-1.97
|
0.79
|
|
2019
|
--
|
--
|
|
2018
|
--
|
--
|
|
2017
|
--
|
--
|
What is the 52 Week High and Low of Metacrine Inc (MTCR)?
The 52-week high and low of Metacrine Inc (MTCR) are Rs -- and Rs -- as of 23-May-2026.
What is the market cap of Metacrine Inc (MTCR)?
Metacrine Inc (MTCR) has a market capitalisation of $ 25 Mln as on 20-Jun-2023. As per SEBI classification, it is a company.
Should I invest in Metacrine Inc (MTCR)?
Before investing in Metacrine Inc (MTCR), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.